Clinical trials: Rectal Cancer, Radiotherapy
Rectal Neoplasms, Neoadjuvant Treatment
Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer
This study is to estimate the pathologic complete response rate of cetuximab, irinotecan, and capecitabine concurrent with radiotherapy given preoperatively in patients with resectable rectal cancer.
- Trial name
- ERBIRIX (NCT00506844)
- Testing
- Cetuximab, Irinotecan, Capecitabine
- Where
- 4 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- National Cancer Center, Korea
Rectal Cancer, Rectal Adenocarcinoma
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
This research study is designed to see if Capecitabine and Lenvatinib in combination with external radiation therapy are effective in treating locally advanced rectal adenocarcinoma in patients who have not yet had surgery, and…
- Trial name
- NCT02935309
- Testing
- Lenvatinib, Capecitabine, External Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Rectal Neoplasms
Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer
This phase I study is designed to determine the maximum tolerant dose of capecitabine when used in preoperative concurrent chemo-radiation for locally advanced rectal patients over 75 years old.
- Trial name
- NCT01584544
- Testing
- capecitabine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chinese Academy of Medical Sciences
Rectal Cancer
Action of Synbiotics on Irradiated GI Mucosa in Rectal Cancer Treatment
The aim of this study is to investigate how bacteria and fibre interact with the epithelial cells of the gastrointestinal mucosa to reduce inflammation and to diminish tissue damage caused by radiation therapy to patients…
- Trial name
- FIPIREX (NCT03420443)
- Testing
- Oat bran, Oat bran and blueberry husks, No oral supplementation
- Volunteers
- 30 people
- Sponsor
- Region Skane
Rectal Cancer Patients
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
This study is a multicenter, prospective, randomized, double-arm, Phase II clinical trial designed to evaluate the efficacy of short-term radiotherapy combined with Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as…
- Trial name
- NCT06911684
- Testing
- lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Total Meso-rectal Excision Versus Transanal Local Excision Followed by Radiotherapy for T2N0M0 Distal Rectal Cancer
A randomized controlled clinical trial to compare the short and long term outcomes of transanal endoscopic microsurgery following radiotherapy or total mesorectal excision for the treatment of Rectal Cancer
- Trial name
- NCT04098471
- Testing
- transanal local excision following radiotherapy, TME
- Where
- China
- Volunteers
- 168 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pathological Response Rate, Circulating Tumour DNA
Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study
Chemoradiation therapy (CRT) followed by surgery is currently the standard of care to treat patients with locally advanced rectal cancer (LARC).
- Trial name
- NCT06035471
- Testing
- MeD-seq
- Volunteers
- 75 people
- Sponsor
- Erasmus Medical Center
Rectal Cancer
Chemoradiation or Brachytherapy for Rectal Cancer
This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the…
- Trial name
- CORRECT (NCT02017704)
- Testing
- Endo-HDR (if randomized to this arm), capecitabine and IMRT (if randomized to this arm), IMRT (intensity modulated radiation therapy)
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rectal Cancer, pMMR (Microsatellite Stable Rectal Cancer)
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
This is a multicenter, phase III, randomized controlled trial. Eligible patients with pMMR/MSS locally advanced rectal cancer will be randomized in a 1:1 ratio to either the experimental group or the control group using…
- Trial name
- NCT07528209
- Testing
- Pucotenlimab combine with CAPOX, CAPOX
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Sun Yat-sen University
Uterine Cervical Neoplasms
The Long-term Benefit of Hydrogel Spacer in Reducing Rectal Radiation Dose in Cervical Cancer Radiation Therapy.
This study is an exploratory study based on the previous study " A prospective, multicenter, randomized, parallel arm-controlled, superiority clinical study to evaluate the role of hydrogel spacer in reducing rectal radiation…
- Trial name
- NCT05902390
- Testing
- hydrogel spacer
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Local Advanced Rectal Cancer, PD-1 Inhibitor
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
This is a randomized, controlled clinical trial based on prior exploratory findings, designed to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with tafolecimab(an anti-PCSK9 inhibitor) and sintilimab…
- Conditions
- Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT
- Trial name
- NCT07686796
- Testing
- Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Guangdong Provincial People's Hospital
Colorectal Carcinoma
Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma
RATIONALE: Monoclonal antibodies, such as Cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.This is an anti-cancer drug which has already been approved…
- Trial name
- NCT00725400
- Testing
- Cetuximab and Radiation Therapy, Surgery and Radiation Therapy
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- American Scitech International
Colorectal Cancer
Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
The purpose of this study is to determine the effects of CyberKnife stereotactic body radiotherapy in combination with irinotecan chemotherapy in patients with colon or rectal cancer that has spread to the liver.
- Trial name
- NCT01847495
- Testing
- Irinotecan, CyberKnife
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Anal Carcinoma
Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy
Randomized study to investigate the efficacy of deep regional hyperthermia in patients with anal carcinoma treated by standard radiochemotherapy with MMC and 5-FU.
- Trial name
- HYCAN (NCT02369939)
- Testing
- Irradiation, Mitomycin C, 5-Fluorouracil
- Where
- Germany
- Volunteers
- 118 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Rectal Cancer, Metastasis
Study of Radiation Therapy in Combination With Xeloda, for Initially Metastatic, Low and Middle Rectal Cancer
In initially metastatic rectal carcinoma, a neo-adjuvant multi-drug chemotherapy is usually performed, followed by a pelvic chemoradiation.
- Conditions
- Rectal Cancer, Metastasis, Radiotherapy
- Trial name
- DESIR (NCT03634202)
- Testing
- IMRT + oral chemotherapy
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Institut Cancerologie de l'Ouest
Rectal Cancer, Radiotherapy, Anal Pain
Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin
Background: According to GLOBOCAN 2022 statistics, colorectal cancer has become the third most common cancer disease worldwide, and also the second leading cause of death.
- Conditions
- Rectal Cancer, Radiotherapy, Anal Pain, Acute Radiation Dermatitis, Anal Canal
- Trial name
- NCT06837831
- Testing
- Control group, Experimental group
- Where
- China
- Volunteers
- 274 people
- Sponsor
- Qianfoshan Hospital
Rectal Cancer
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
The goal of this Phase 2 trial is to evaluate a neoadjuvant treatment mode for locally advanced rectal cancer (LARC), consisting of radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102).
- Trial name
- TASLARC (NCT05965531)
- Testing
- Trifluridine/Tipiracil, intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Sun Yat-sen University
Anal Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00003596
- Testing
- cisplatin, fluorouracil, mitomycin C
- Where
- 485 sites in United States, South Africa
- Volunteers
- 682 people
- Sponsor
- Radiation Therapy Oncology Group
Radiotherapy, Immunotherapy
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
This study is a randomized controlled phase II trial to evaluate the efficacy of the combination of stereotactic body radiation therapy (SBRT) and immunotherapy with postoperative chemotherapy in colorectal cancer liver…
- Conditions
- Radiotherapy, Immunotherapy, Liver Metastases, Colorectal Cancer
- Trial name
- IMPROVE (NCT06120127)
- Testing
- SBRT, Chemotherapy, PD-1 antibody
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Recurrent Rectal Cancer
Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer
The study is a prospective, single-center, single-arm, phase II clinical trial. Patients with pelvic recurrent rectal cancer aged from 18 to 75 years, Eastern Cooperative Oncology Group performance status of 0-1, will receive…
- Trial name
- TRACER (NCT06751394)
- Testing
- PD-1 antibody (Toripalimab), Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University